DATE: September 26, 2017
TIME: 6:00AM PDT

Despite a few decades of proteomics research and the apparent discovery of multiple protein biomarkers, the number of biomarkers that have been developed to the stage of being used routinely in clinical practice is disappointingly low. So, it's clear that whilst there’s huge interest in the development of new biomarkers and major drivers for this to happen: including the pharmaceutical industry’s need to better stratify patients for effective treatment, as yet biomarker development and delivery is proving very challenging.

This presentation will cover:

Start at the end: identifying clinical need

Protein biomarker discovery

From candidate protein biomarkers to peptide MRM assays – advantages for biomarker evaluation

Delivery of robust and routine peptide MRM assays – from sample preparation to test report     

While further work is still needed, the role of Agilent solutions in each of these key research stages will be shown and will support our conclusion that the pathway for implementation of peptide MRM assays is relatively straightforward and can be implemented in future clinical diagnostics settings.

See more about how Agilent is helping Stephen Pennington with his research.

Don’t miss Stephen Pennington’s presentation at MSACL US in January 2018. Follow Agilent’s Clinical Research LinkedIn page for upcoming MSACL announcements.

View Agilent’s Proven Solutions for Clinical Research & Forensic Toxicology Compendium.

If you would like to speak with an Agilent Sales Rep or get a quote, let us know!

For Research Use Only.  Not for use in diagnostic procedures.